FIG 4.

DoR and survival. Kaplan-Meier curves of (A) DoR, (B) PFS, and (C) OS are shown for patients with TRK fusion–positive lung cancers treated with larotrectinib. At the data cutoff, the median DoR, PFS, and OS were 33.9 months (95% CI, 5.6 to 33.9), 35.4 months (95% CI, 5.3 to 35.4), and 40.7 months (95% CI, 17.2 to NE), respectively. DoR, PFS, and OS rates at 12 months are indicated with vertical dashed lines on each curve. DoR, duration of response; NE, not estimable; OS, overall survival; PFS, progression-free survival; TRK, tropomyosin receptor kinase.